Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences outlines its 2025 business, emphasizing leadership in structural heart therapies. Transcatheter Aortic Valve Replacement (TAVR) remains the core franchise, representing 74% of 2025 net sales, while Transcatheter Mitral and Tricuspid Therapies contributed 9% and Surgical Structural Heart valves 17%.
The company reports an aggregate market value of common stock held by non‑affiliates of $45,899,189,298 as of June 30, 2025, with 580.8 million shares outstanding as of January 31, 2026. Research and development spending rose about 2% and reached roughly 18% of 2025 sales, reflecting heavy investment in next‑generation TAVR, TMTT and surgical platforms.
Edwards generated 58% of net sales in the United States and 42% internationally, operates in about 100 countries, and employed roughly 16,000 people as of December 31, 2025. The filing details extensive risk factors, including innovation and clinical trial execution, manufacturing quality, competition from Medtronic and Abbott, reimbursement pressure, global regulatory change, cybersecurity, AI governance, and tax and compliance exposure.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported a tax-related share disposition. On February 22, 2026, he transferred 432 shares of common stock at a price of $79.78 per share to cover tax withholding. After this transaction, he directly owns about 33,933.9103 shares.
Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported a Form 4 showing a tax-withholding disposition of 176 shares of common stock on February 22, 2026. The shares were disposed of at a reported price of $79.78 per share, and he now directly holds about 9,089.4805 shares.
Ullem Scott B. reported disposition transactions in a Form 4 filing for EW. The filing lists transactions totaling 199 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 39,699 shares.
Lippis Daniel J. reported multiple insider transaction types in a Form 4 filing for EW. The filing lists transactions totaling 13,276 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 34,366 shares.
Edwards Lifesciences CEO Bernard J. Zovighian reported several share transactions. On February 12, 2026, he exercised employee stock options covering 25,350 shares of common stock at an exercise price of $59.2567 per share. On the same day, he sold 2,532 shares at a weighted average price of $77.1287 and 19,898 shares at a weighted average price of $76.6133 in open-market transactions.
On February 13, 2026, he reported bona fide gifts of 2,920 shares of common stock at $0.0000 per share in a direct account and 2,920 shares reflected as indirectly held "By Trust." After these transactions, he directly held 80,976 shares, with an additional 11,516.5511 shares held indirectly by a trust and 3,655.5854 shares represented in his 401(k) plan.
Edwards Lifesciences Corp insider Bernard J Zovighian filed a Rule 144 notice to sell 22,430 shares of common stock, with an aggregate market value of $1,719,742.00. The proposed sale is through Charles Schwab & Co., Inc. on the NYSE around 02/12/2026.
The notice states that 580,300,000 shares of common stock were outstanding; this is a baseline figure, not the amount being sold. It also lists prior sales over the past three months of 21,487 and 3,863 Edwards Lifesciences shares, with gross proceeds of $1,831,006.00 and $322,367.00, respectively.
Edwards Lifesciences reported strong growth for the quarter and year ended Dec. 31, 2025, while GAAP earnings were pressured by large one‑time charges. Q4 net sales rose 13.3% to $1.57 billion, led by Transcatheter Aortic Valve Replacement (TAVR) sales of $1.16 billion, up 12.0%, and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales of $156 million, which grew more than 40%.
Q4 diluted EPS from continuing operations was $0.11, while adjusted EPS was $0.58, reflecting exclusions such as $208.6 million of certain litigation expenses and a $99.8 million loss on impairment in the quarter. Full‑year 2025 net sales increased 11.5% to $6.07 billion, with TAVR and TMTT both delivering double‑digit constant‑currency growth.
The company guided to 2026 constant‑currency sales growth of 8–10% and expects TMTT revenue of $740–$780 million, implying 35–45% growth. Edwards also targets 2026 adjusted EPS of $2.90–$3.05 and an adjusted operating margin at the high end of a 28–29% range, supported by a broad structural heart portfolio and multiple product and clinical trial catalysts.
Edwards Lifesciences Corporation reports that the United States District Court for the District of Columbia has granted the U.S. Federal Trade Commission’s motion for an injunction blocking Edwards’ proposed acquisition of JenaValve Technology, Inc. As a direct result of this court action, Edwards states that it will not acquire JenaValve.
The update is presented as an other event and is based on a company press release dated January 9, 2026, which is attached as an exhibit. The filing focuses on the legal outcome affecting this specific transaction and does not provide additional financial figures or broader business updates.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related share sale. On 01/09/2026, he exercised an Employee Stock Option for 1,019 shares of common stock at an exercise price of $59.2567 per share and acquired the underlying shares. On the same day, he sold 1,019 shares of common stock at a weighted average price of $85.7037 per share, in multiple trades executed between $85.45 and $85.95.
After these transactions, Lippis directly beneficially owned 22,001.9103 shares of Edwards Lifesciences common stock and 4,076 Employee Stock Options (right to acquire). The filing states that these transactions were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2025.